Skip to main content
. 2020 Oct 7;9(10):3214. doi: 10.3390/jcm9103214

Figure 4.

Figure 4

Combination treatment with PI3K and CDK 4/6 inhibitors display a synergistic effect in PIK3CA-WT tumors. (a) Average ZIP synergy scores, calculated by SynergyFinder 2.0, of UT-SCC60A and UM-SCC47 following treatment with a combination of abemaciclib and BYL719. (b) Dose–response matrix and ZIP synergy score surface plots of UT-SCC60A following treatment with a combination of BYL719 and abemaciclib. (c) Signaling pathway protein expression in UM-SCC47 and UT-SCC60A following treatment with either BYL719 or abemaciclib monotherapy or combination therapy.